Seventy-three parturients for elective Caesarean section were allocated randomly to receive extradural block with 20 ml of either 0.5% ropivacaine or 0.5% bupivacaine. If the block did not reach T6 within 30 min, another 5 ml of solution was given. If needed, a further 5 ml was given 45 min after the main dose. The mean total dose of bupivacaine was 23.1 ml (n = 35) and of ropivacaine 23.7 ml (n = 37). There was no significant difference between the groups in the profile of sensory block produced. There was no significant difference in the time of onset, or intensity of motor block between the groups but the duration of motor block was significantly shorter in the ropivacaine group. There was no significant difference in neonatal outcome, as assessed by Apgar score, umbilical cord bloodgas tensions at delivery or the neurological and adaptive capacity score 2 and 24 h after delivery. (Br. J. Anaesth. 1995; 74: 512-516) 
Patients and methods
After obtaining local Ethics Committee approval, and written consent to be included in a double-blind, randomized comparison of extradural 0.5 % ropivacaine and 0.5 % bupivacaine, we studied 73 pregnant women, ASA I or II, undergoing elective extradural Caesarean section with or without tubal ligation. All had a full term (> 36 weeks) singleton fetus and were aged ^ 18 yr, height ^150 cm, body weight 50-110 kg and with an estimated fetal weight of ^ 2500 g. Exclusions included women with diabetes mellitus, pre-eclampsia, psychiatric disease, history of drug abuse or known allergy to amide local anaesthetics.
All women were premedicated with oral ranitidine and given a preload of Hartmann's solution 500 ml. They were then allocated randomly to receive extradural block using either 0.5% ropivacaine or 0.5 % bupivacaine in a double-blind design. The extradural block was performed using a 16-gauge Tuohy needle in the L3-4 interspace (or alternatively the L2-3 interspace if for any reason insertion at L3-4 was not possible) using a midline approach with the patient in the lateral position. The extradural space was identified by loss of resistance to saline. Provided neither cerebrospinal fluid nor blood was obtained on aspiration, an extradural catheter was inserted 3-5 cm in a cephalad direction and a test dose of 3 ml of study drug was injected. If there were no untoward effects after 5 min, the main dose of 17 ml of study drug was injected over 4 min. Women were kept in one or other lateral position as appropriate to promote spread of block, until surgery commenced.
Surgery was not begun until analgesia to pinprick was achieved bilaterally to T6. If the block did not reach T6 within 30 min, an additional 5 ml of study drug was given. If needed, another 5 ml was given 45 min after the main dose. If the block did not reach T6 after another 15 min, the patient was withdrawn from further efficacy assessments and the extradural converted to spinal or general anaesthesia. If surgery had started and the maximum volume (30 ml) of the study drug had not been given, and if discomfort was felt, an additional dose of the study drug up to a total of 30 ml could be given. The quality of anaesthesia was not then regarded as excellent.
An automatic sphygmomanometer was used to record maternal heart rate and systolic and diastolic arterial pressures. Recordings were made before the test dose and then every 5 min until the end of surgery. Recordings were then every 30 min until 3 h after the end of the main dose of local anaesthetic, unless more frequent recordings were indicated clinically. Hypotension (defined as systolic arterial pressure less than 100 mm Hg) was treated with Hartmann's solution up to 1500 ml (including preload), 6-mg boluses of ephedrine, or both.
After surgery, the patients were allowed morphine 10 mg i.m.j diclofenac 100 mg per rectum, or both, for pain or discomfort, at the discretion of the anaesthetist. No drugs were given extradurally until recovery of motor and sensory function was complete.
The upper and lower limits of analgesia to pinprick were determined bilaterally 5, 10, 15 and 30 min (45 and 60 min if applicable) after the main dose, and thereafter every 30 min until return of normal sensation. During surgery only the upper limits of sensory analgesia were measured.
Motor block was assessed bilaterally at the same time intervals using the modified Bromage scale: 0 = no paralysis (full flexion of hip, knee and foot), 1 = unable to flex hip (able to flex knee and ankle), 2 = unable to flex knee (able to flex foot only), 3 = unable to flex hip, knee or ankle joint. Motor block assessments were not made during surgery.
At the end of operation, the overall quality of analgesia and neuromuscular block were judged by the anaesthetist and surgeon, respectively.
FETAL ASSESSMENT
Fetal heart rate was measured continuously by cardiotocography (CTG) during extension of the extradural block, and any adverse events were recorded.
Neonatal welfare was evaluated by Apgar scores 1 and 5 min after delivery and by umbilical venous and arterial blood-gas analysis. For the purposes of the study, an abnormal Apgar score was defined as < 7 and fetal acidosis by an umbilical arterial or venous blood pH less than 7.17 or 7.27, respectively. Neonates were assessed also by the neurological and adaptive capacity score (NACS) performed 2 and 24 h after delivery, according to a previously described method [8] . NACS gives a numerical score with a maximum of 40: NACS ^ 35 is considered to denote a vigorous baby [8] . The proportion of patients with NACS < 35 in each of the groups was compared. The NACS examination and maternal sensory and motor block assessments were performed by one of the authors (R. P. G.) in all cases.
Mothers and babies were followed-up daily in hospital and 2-3 weeks after delivery to record any adverse events.
STATISTICAL ANALYSIS
Mean values of the left and right sides were used in the analyses of maternal sensory and motor block. For maternal and fetal qualitative variables, the hypothesis of equal proportions of the responses for the two treatments was tested using the chi-square test. If the expected frequency in any cell was less than 5, Fisher's exact test was used. The null hypothesis that the onset and duration of motor block were similar for the two treatments was tested using the two-tailed Wilcoxon rank sum test. The null hypothesis that the extent of sensory block with time was the same for both treatments was tested by multivariate repeated measures analysis BMDP-5V, which allowed for within-patient correlation between measurements [9] . The general autoregression structure for the within-patient covariance matrix was found to best fit the data. For all statistical tests, an outcome with a two-tailed P value of 0.05 or less was considered statistically significant. The sample size was considered sufficient to allow the detection of clinically important differences between the treatments, based on unpublished phase II studies. A difference in duration of motor block of 1 h was considered clinically important.
Results
Thirty-seven patients received ropivacaine and 36 patients bupivacaine. One patient, in the bupivacaine group, developed a very limited block, which in retrospect was caused by the extradural catheter slipping back 3 cm during injection of the main dose of local anaesthetic. This patient was excluded from evaluation of efficacy. There were no accidental dural punctures. The groups were similar in age, weight, height, the number of ASA I and II patients and mean dose of local anaesthetic used (table 1) .
In four patients in the ropivacaine group and three in the bupivacaine group, the extradural was converted to spinal or general anaesthesia because the block did not reach T6 after 60 min or surgical anaesthesia was inadequate. These patients were excluded from further analysis of efficacy and assessment of neonatal outcome. Figure 1 shows the segmented sensory analgesia to pinprick in each of the treatment groups. In all patients the lower limit of sensory analgesia was S5 immediately before and after surgery, and so was assumed to be S5 during surgery. There was no evidence of variation (in each patient) with time being different between the two groups by multivariate repeated measures analysis. The maximum cephalic level of pinprick analgesia (table 2) did not differ significantly between the groups. Global assessment of the quality of analgesia during surgery revealed six patients in the bupivacaine group who had unsatisfactory analgesia compared with one in the ropivacaine group. After operation 11 patients in the ropivacaine group were given i.m. morphine and only four in the bupivacaine group. These differences were not significant. Figure 2 shows the proportion of patients who developed motor block in each of the treatment groups. Results for 45, 60 and 90 min after the main dose are not included as in more than 20% of patients motor block was not assessed because surgery was in progress.
SENSORY BLOCK AND QUALITY OF BLOCK
of maternal sensory and motor block, and quality of analgesia and neuromuscular block (median [range] or number). Significantly shorter duration than bupivacaine:Grade 1 Grade 2 Grade 3 Duration (h) Grade 1 Grade 2 Grade 3 No motor block Quality of neuromuscular block Excellent Satisfactory Unsatisfactory Not applicable Max. upper sensory level Quality of analgesia Excellent Satisfactory Unsatisfactory Not applicable Postoperative analgesia
MOTOR BLOCK
The onset time of motor block did not differ significantly between the two groups but the durations of grade 1 and 2 motor block were 90-I significantly shorter in the ropivacaine than the bupivacaine group (table 2) . There was no significant difference in the number of patients who developed motor block (the intensity of motor block) grades 1, 2 or 3 between the treatment groups (table 2) . No patient in the study had unsatisfactory neuromuscular block for surgery.
NEONATAL OUTCOME (table 3) The CTG recording before surgery was normal in all cases. The proportion of babies with Apgar scores < 7, 1 min after delivery did not differ significantly between the groups. No neonate in the study had an Apgar score < 7, 5 min after delivery. There was no significant difference between the groups in the number of umbilical arterial or venous pH values below the lower limit of the reference range.
Two neonates in the ropivacaine group and one in the bupivacaine group were unable to have NACS completed because they developed transient tach- ypnoea of the newborn (TTN) after delivery. There was no significant difference between the groups in the proportion of neonates with NACS < 35 in each of the treatment groups.
ADVERSE EFFECTS
The immediate adverse sequelae are presented in table 4. The commonest adverse effect was hypotension. Figure 3 shows the changes in arterial pressure in the two groups with time. Nausea was a 515 frequent mild adverse effect but did not differ significantly between groups. One patient in the ropivacaine group developed haemorrhagic shock from uterine bleeding after delivery. She had no long-term sequelae after adequate blood transfusion. All neonates who developed TTN required admission to the neonatal intensive care unit for 1-3 days. They all remained well after discharge from the unit. At the 2-3-week follow-up, one patient from the ropivacaine group reported back pain and another a persistent headache which was not typical of postdural puncture headache. In both cases the symptoms started 2 weeks after surgery. One patient in the bupivacaine group reported delayed wound healing.
Discussion
Several studies have demonstrated a longer duration of sensory block with bupivacaine than ropivacaine [10, 11] . Our study however, confirmed the results of other workers [5, 7] that in equal doses and concentrations, the profile of sensory block with time is the same for ropivacaine and bupivacaine.
Our data showed that the incidence of, and time to, onset of motor block were similar in patients who received ropivacaine and bupivacaine but the duration of motor block (Bromage score 1 and 2) was significantly shorter in patients who received ropivacaine. Several other studies have also found no difference in onset time and a shorter duration of motor block [7, 10, 11] , although one study found that motor block was not only of shorter duration in patients who received ropivacaine, it was also later in onset [5] . In our study the intensity of motor block did not differ significantly between groups. Other workers have found that ropivacaine produced a less intense motor block [7, 11] .
In our study, extradural block was inadequate for surgery in 10% of patients in each treatment group. Previous studies of elective Caesarean section under extradural anaesthesia using 0.5 % plain bupivacaine also had a high incidence of inadequate block [12, 13] with 20-30% of patients requiring supplementary analgesia with nitrous oxide or opioids (an option not available in our study). The addition of opioids to extradural ropivacaine may reduce this problem, as it does with bupivacaine.
The most frequent maternal adverse effect was hypotension. Kerkkamp and Gielen [14] used transthoracic electrical bioimpedence to study haemodynamic changes with extradural administration of bupivacaine and ropivacaine and found the effects were similar. We also found that the incidence of hypotension was the same in the two groups. The frequency of other adverse effects was within normal limits and not significantly different between the two groups. The 10% incidence of TTN was to be expected [15] .
Neurobehavioural scoring systems have been used to detect the neonatal effects of anaesthetic agents administered to parturients. The early neonatal neurobehavioural scale (ENNS) was developed by Scanlon and colleagues and used to assess the neonatal effects of extradural local anaesthetics given to parturients [16] . Using ENNS, no adverse neonatal effects have been detected with bupivacaine given extradurally for analgesia during labour [17] or for Caesarean section [18] . The NACS was developed by Amiel-Tisen and co-workers [8] and embodies some elements of Scanlon's ENNS. The test specifically uses items that have been demonstrated to be affected by obstetric medications, that are easy to perform, require no complicated equipment, are quickly observable, simple to score and possess a high inter-observer reliability. A study using NACS demonstrated no adverse effects on the neonate of bupivacaine given for extradural analgesia during labour [19] . Our own results showed no difference in the incidence of a low NACS (< 35) between the ropivacaine and bupivacaine groups, and also the number of neonates with poor Apgar scores or umbilical blood-gas tensions was not significantly different between the two groups. None of the neonates with abnormal values had long-term sequelae. Hence extradural ropivacaine in the doses used in our study appeared to have no adverse effect on neonatal welfare.
In summary, we found that 0.5 % ropivacaine and 0.5 % bupivacaine produced a similar extent and duration of sensory analgesia and both agents produced equally satisfactory block for Caesarean section. The more rapid recovery of leg mobility with 0.5 % ropivacaine may be advantageous.
